Skip to content
ESPT
MARKETS / NASDAQ / Health care / Pharmaceuticals / ACAD
NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP

Acadia Pharmaceuticals Inc. ACAD

17 fiscal years on record · USD · FY2025 reported · SEC filings only
$1.1B
▲ 11.9% YoY
$391.0M
▲ 72.7% YoY
$105.1M
▼ 33.1% YoY

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

ACADIA Pharmaceuticals Inc. markets NUPLAZID (pimavanserin), the first and only FDA-approved drug for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis, and DAYBUE, the first and only approved drug for the treatment of Rett syndrome. It organizes these two commercial products into two core franchises, in neurological disease and rare disease. At December 31, 2025, it had a total of 798 employees, 796 of whom were full-time. Its global headquarters are in San Diego, California, and it also has substantial operations in Princeton, New Jersey and European headquarters in Zug, Switzerland. It holds worldwide commercialization rights to NUPLAZID for all indications. ACADIA was originally incorporated in Vermont in 1993 as Receptor Technologies, Inc., and reincorporated in Delaware in 1997.

Written from the business description in ACADIA PHARMACEUTICALS INC's annual report to the U.S. Securities and Exchange Commission, filed 26 February 2026. Every sentence was checked against that document before publication.

Growth

USD 1.1B
Revenue, FY2025 · full 17-year series below
Revenue $B Net income $B
FY2025 · Revenue 1.1 · Net income 0.4
0.5B1.0B-0.1B-0.3B
2009201220152018202120242025
Compound annual growth
+27.5%
+19.4%
+165.7%
+24.1%
+24.2%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +19.4% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

36 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating 9.8% · Net 36.5%
-100000%-200000%
200920172025
ROE
FY2025 · ROE 39.9%
20%40%60%-100%-200%-300%
200920172025
Three returns, three denominators.
Gross margin91.7%
Operating margin9.8%
Net margin36.5%
EBITDAUSD 105.7M

Each USD of equity produced 40 cents of profit this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF 105.1
100M200M-100M-200M
200920172025
Dividends paid·
Net buybacks·
Share of profit·
Consecutive raises·

Total assetsUSD 1.6B
EquityUSD 1.2B
CashUSD 177.7M
Current ratio3.83×

Equity funds 78% of total assets.

The 17-year record

17 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
ACAD, 17-year financial record
Metric 20252024202320222021202020192018201720162015201420132012201120102009
Revenue $B1.11.00.70.50.50.40.30.20.10.00.00.00.00.00.00.00.0
Operating income $B0.10.2−0.1−0.2−0.2−0.3−0.2−0.2−0.3−0.3−0.2−0.1−0.0−0.0−0.00.0−0.0
EBITDA $B0.10.2−0.1−0.2−0.2−0.3−0.2−0.2−0.3−0.3−0.2−0.1−0.0−0.0−0.00.0−0.0
Income tax $B−0.30.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0◌
Net income $B0.40.2−0.1−0.2−0.2−0.3−0.2−0.2−0.3−0.3−0.2−0.1−0.0−0.0−0.00.0−0.0
Free cash flow $B0.10.20.0−0.1−0.1−0.1−0.2−0.2−0.2−0.2−0.1−0.1−0.0◌−0.0◌◌
EPS, diluted $2.301.36−0.37−1.34−1.05−1.79−1.60−1.94−2.36−2.34−1.63−0.95−0.44−0.38−0.440.39−1.20
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend—————————————————
ROE %39.938.9−14.7−45.9−28.7−42.5−39.9−60.2−67.8−75.6−64.6−37.6−28.4−38.5−85.872.4−372.7
Shares out B0.170.170.160.160.160.160.160.140.120.120.100.100.090.070.050.04◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

MCK · COR · CAH · JNJ · HCA · LLY
Provenance

Company facts, as filed

How we verify · 0 failures in 74 reconciliationsAUDITED

Reconciled in 17 of the 17 fiscal years we could check. Nine checks were skipped: cost of revenue is not tagged before 2016. Six checks were skipped: the balance sheet is not tagged before 2010. Two checks were skipped: EPS is not tagged before 2009.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2009

Share this section

Download image